Pharm Exec Podcast: Recent Episodes
Pharmaceutical Executive Magazine
Pharm Exec podcast goes beyond the pages of Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.
Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.
Link to Honeycomb Health video: https://www.pharmexec.com/view/going-beyond-visuals-to-connect-with-diverse-audiences
Currax Pharmaceuticals CEO, George Hampton discusses what patient success has looked like for their oral anti-obesity medication, how expanded access can help with the world's obesity epidemic, when prices should come down, and much more.
In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with female KOLs that she's been fortunate enough to speak with over this past month for content across a few of our brands.
Featured in this episode are:
Emma Banks, CEO, ramarketing
Jill Jaroch, Senior Director, Women’s Health & Urology Marketing, Astellas
Marie Teil, Global Head, UCB’s Women of Childbearing Age Program
Julia Lakeland, Chief Product Office, uMotif
If you enjoyed this episode of our podcast, we encourage you to seek out the longer version of each of these videos—Linked on our website!
Ian Baer, Founder and Chief Soothsayer, Sooth, discusses their recent data and research about some massive behavioral shifts occurring across Gen-Z, and how pharmaceutical companies and healthcare advertising agencies can adapt their strategies to attract the ever elusive generation.
Jingsong Wang, Chairman of Nona Biosciences, discusses Nona Biosciences’ recent exclusive license agreement with Pfizer Inc. for the development and commercialization of HBM9033, an innovative antibody-drug conjugate (ADC) targeting MSLN, a key antigen in various solid tumors. Wang believes that the partnership will significantly advance Nona's Harbour Mice® platform and ADC ecosystem.
Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
Sameer Lal, Sr. Vice President, Enterprise Medical Solutions at Indegene, discusses findings from their new study about Reshaping Pharmacovigilance in the age of AI, digital/generative AI opportunities, how quickly the industry is adopting this technology, and much more.
Dr. Julien Boisdron, Global Head of OneMedical / Chief Medical Officer Roche Diabetes Care, discusses the current standard for diabetes care, the importance of patient advocacy and mental health, what the future of this space holds, and much more.
Edward Triebell, Commercial Executive Director for MRN Technologies, discusses the biggest digital trends in clinical research right now, how COVID-19 impacted the use of digital within sponsors and CROs, what the future of DCT services looks like, and much more.
David Klein, co founder and CEO of Click Therapeutics, discusses the new FDA SaMD guidance, the clear differences between companion apps and SaMD, and gives insight into what to expect from this combination in the future.
In this exclusive Pharm Exec Podcast episode with Paul Biondi, executive partner at Flagship Pioneering (the venture creation firm behind Moderna and many other life science firms) and president of Pioneering Medicines, Meg Rivers, managing editor, asks Biondi about 1) the process of founding a company; 2) what factors they consider when deciding whether to partner with a pharmaceutical company (like your partnership with Novo Nordisk) or a foundation (like your partnership with the Cystic Fibrosis Foundation)—along with what makes one organization stand out from another; 3) where science is booming in pharma right now; 4) deciding whether to found a company looking to launch innovations in an existing space vs. pursue innovations in an untapped space; and 5) signs that a company will achieve commercial success from early on.
Commercialization is a tough road to navigate even for the most established bio/pharmaceutical therapies. But as cell and gene therapies (CGTs) continue to form roots and make a splash worldwide—but specifically in the US—commercialization forms its own version of standardization and best practices.
In this exclusive interview with Pharmaceutical Executive, Lung-I Cheng, vice president of CGT, Cencora (formerly AmerisourceBergen), discusses:
1) defining CGT commercialization strategies and foundational knowledge—and the best music metaphor
2) what he wishes companies knew about commercialization strategies
3) common knowledge gaps of CGTs
4) how CGT developers can overcome key challenges, including those related to patient access, regulatory requirements, and market access
5) how planning for allogeneic cell therapies differs from autologous cell therapies and gene therapies
6) how companies can demonstrate CGT value as more products enter the development pipeline (and competition intensifies)
7) when to start planning a CGT commercialization strategy
8) predictions for the CGT market in five years
Gerald Kierce, co founder and CEO of Trustible and Andrew Gamino-Cheong, the company's CTO and co founder, delve into the realm of artificial intelligence discussing Trustible's mission and its pioneering efforts to ensure ethical AI use particularly in the pharmaceutical industry, and how it navigates complex AI regulations across the globe.
How to price a bio/pharmaceutical drug is one of the most complex topics for pharmaceutical executives, as there are many factors to consider. Alice Valder Curran, life sciences regulatory expert and partner, Hogan Lovells LLP, reveals the following to Pharmaceutical Executive® in this exclusive Pharm Exec Podcast interview: 1) the biggest drug pricing challenges today; 2) current efforts to lower drug pricing; 3) what companies should consider as it relates to drug pricing from a legal perspective; 3) the status of the Inflation Reduction Act (IRA), specifically what should companies be watching for; 4) potential impact on companies from the IRA; 5) IRA milestones we will be seeing through the end of the year; and 6) drug pricing recommendations (from a legal perspective).
ACT podcast: https://www.appliedclinicaltrialsonline.com/editorial-podcasts
In this podcast, Sharlene Jenner, vice president of engagement strategy at Abelson Taylor and professor of AI and personalization for digital marketers at Southern Methodist University, leads a panel of five industry leaders in a roundtable discussion. The conversation delves into the practicalities of current AI applications and confronts the ethical and regulatory issues related to the technology. The panelists also explore the direct consequences and prospective implications of AI, providing listeners with a snapshot of the present and an outlook on the transformative potential of emerging technologies in the pharmaceutical marketing sphere.
The panel consists of: Faruk Capan, chief innovation officer, EVERSANA, and CEO, EVERSANA INTOUCH; Anurag Banerjee, CEO and founder, Quilt.AI; Jeff Headd, vice president, commercial data science, The Janssen Pharmaceutical Companies of Johnson & Johnson; and Stephen Onikoro, senior principal, head of strategy, PharmaForceIQ.
Sponsored by: ZS https://www.zs.com/
In this podcast, Mohit Manrao, the SVP and head of US oncology at AstraZeneca, shares his journey from growing up in Northern India with aspirations of becoming a doctor, to leading oncology initiatives at AstraZeneca in the US. A central strategy to ultimately eliminate cancer includes ensuring that the latest scientific advancements are accessible to patients in every zip code and the necessity of integrating the patient perspective at every stage—from early discovery to commercialization, recognizing the importance of diverse patient needs, non-invasive diagnostics, and alleviating challenges in access to screenings and treatments.
Welcome to a riveting episode of the Pharm Exec podcast, where we dive headfirst into the transformative world of AI in healthcare with Sharlene Jenner, vice president of engagement strategy with the award-winning agency Abelson Taylor. This enlightening conversation traverses the advancements and potential risks of AI, the revolution it is stirring in pharmaceutical marketing, and its game-changing role in understanding complex protein structures. Amid the rapid innovation, we explore the urgent need for ethical guidelines and regulations to keep pace with technology.
We all know that the pharma industry is about people—bettering the lives of others through good research, life-changing pharmaceuticals, and keeping the patient front and center. But Jag Dosanjh, president, U.S. neuroscience and eye care, AbbVie, lives that principal. In this podcast episode, Meg Rivers, managing editor, talks with Dosanjh about what he calls a “people business” and his approach to leadership. He starts his career in the medical sales space before working in many different roles and therapeutic areas before ultimately landing at AbbVie. He was also nominated HBA’s mentor of the year and shares insights into being a good leader and mentor. One of his tips was: “If you listen well, you can learn well.” In addition, he emphasized the importance of curiosity, learning, and the pursuit of a smile.
This Pharma 50 companion episode delves into the vital topic of trust within the pharmaceutical industry. Morton Nielsen, senior partner for the life sciences practice at Wittkieffer, dissects the concept, drawing on parallels to Maslow's hierarchy of needs, and discusses practical methods for measuring and operationally improving trust. This episode is a must-listen for those interested in understanding the current state and future evolution of trust in the pharmaceutical sector, an industry where trust forms a fundamental pillar for delivering on its mission statement.
Read the 2023 Pharma 50 article here: https://www.pharmexec.com/view/2023-pharm-exec-top-50-companies
The 2023 Emerging Pharma Leaders share with Meg Rivers, managing editor of Pharmaceutical Executive, and the editorial team what makes a good leader, what has made them the proudest in their career, lessons they wish they had known when starting out, and more. Congratulations to the 2023 Emerging Pharma Leaders: Natasha A. Hernday, chief business officer, Seagen; Simon Holland, vice president, women's health commercial lead, Organon; Justin To, chief operating officer, skeletal dysplasias and gene therapy, Bridge Bio; Frank Watanabe, president and CEO, Arcutis Biotherapeutics; and Hanadie Yousef, PhD, co-founder and CEO, Juvena Therapeutics. SPONSOR: APEX Awardshttps://www.pharmexec.com/apex-awards
Launching a drug and receiving approvals—whether it’s in the U.S. or globally—is challenging to navigate. It’s a process that often takes years and a lot of back-and-forth communication with regulatory bodies. In this episode, Torrey Cope, partner, food, drug, and medical device practice, Sidley Austin LLP, discusses drug approvals and drug launches from a legal perspective, including 1) his work as an attorney; 2) tips for drug approvals from a legal perspective; 3) current regulatory challenges the industry is facing in the U.S.; 4) the shift away from a one-sized-fits all approach to marketing and global launches; 5) tips for companies navigating the regulatory landscape in the U.S.; 6) when to launch a drug in a country outside of the U.S.; and 7) drug pricing. Join Meg Rivers, managing editor, as she dives into this topic with Cope.
In this episode of the Pharmaceutical Executive Podcast, we dive into a conversation with Frank Watanabe, president and CEO of Arcutis, a medical dermatology company with a patient-first approach. Discover how Arcutis is transforming the dermatology landscape with its innovative product offerings, such as FDA-approved Zoryve for topical treatment of plaque psoriasis and their upcoming products for seborrheic dermatitis and atopic dermatitis. Learn about the company's guiding principles, the importance of keeping patients at the forefront of decision-making, and the need for further innovation in the dermatology sector after decades of stagnation.
Elizabeth (Beth) Garner, chief scientific officer for Ferring Pharmaceuticals, speaks with Meg Rivers, managing editor, about: 1) her journey into the world of pharma, including her transition from being a physician/surgeon to working in clinical trials; 2) both women’s and men’s reproductive health; 3) the latest technologies in fertility treatment (for men and women); 4) unmet needs in fertility care; 5) trends in contraception and fertility treatment; 6) DE&I and access to care, and 7) predictions for the contraception and fertility treatment spaces in the coming years
Two companies join forces to unlock the hidden potential in existing drugs to save lives suffering from rare diseases. In 2010, Dr. David Fajgenbaum, co-founder, Every Cure, was a third-year medical student when he became critically ill with Castleman disease (CD). After months of hospitalization and in critical condition, nearly dying several times, he launched an initiative to find treatments to save his life and others. Fajgenbaum and Michelle Longmire, CEO and co-founder, Medable—both physicians and entrepreneurs—team up in a new partnership to treat rare diseases by repurposing drugs that arealready on the market and finding other therapeutic areas where these drugs can have an impact.
Cathi Ahearn is a seasoned biotechnology leaders with formative stints at Genentech, Roche, and now at Bristol Myers Squibb, as SVP of worldwide commercial portfolio strategy. Cathi is focused on one goal: shortening the path between creating medical innovation and getting that innovation to patients. Cathi chats with senior editor at Pharmaceutical Executive about her experiences in the past 20+ years and most importantly, the power of cross-functional collaboration, bringing different teams together and tearing down silos that limit the impact new innovations can have for patients.
Across most industries, finding and keeping the right talent is a constant challenge for companies. This challenge is perhaps even more prevalent in the pharmaceutical industry, which requires a significant amount of specialization. Rebekah Martin, senior VP of reward, inclusion, and talent acquisition for AstraZeneca, discusses recruiting talent in pharma with Meg Rivers, managing editor. Specifically, Martin talks about 1) her journey into pharma; 2) reasons that finding and keeping talent is a challenge today in pharma; 3) ways to address the need for talent; 4) identifying and nurturing young talent; 5) increasing interest in working in bio/pharma, particularly among students; 6) how talent can be nurtured; and 7)how the industry can support and encourage diversity in the workforce.
Join Tina Fascetti, CCO of The Agency Network at MJH Life Sciences for a podcast interview with Ryan Potter, ACD Art, and Priscila Ramos, ACD Copy, from McCann Health as they share the "behind the creative" story of their Apex Award-winning consumer creative campaign for Entresto. The Apex Awards is judged by none other than the people they are aimed to connect with, the patients themselves.
In his position, Faruk Capan leads thousands of employees around the globe with a focus on bold innovation—one can imagine how excited he is about Chat GPT, which set the record for fastest-growing user base in history. Senior editor Fran Pollaro and Faruk go back and forth about positives, negatives, hopes, and fears attached to generative AI for us as regular humans, and as pharma marketers. The pair delve into content creation, creative, video production, research, sales and marketing…it’s clear that we’re on the precipice of life-changing innovation.
It is no easy feat to break into a male-dominated field as a woman, no less the bio/pharmaceutical industry. Piper Trelstad, PhD, head of chemistry, manufacturing, and control (CMC), Bill & Melinda Gates Medical Research Institute, shares with Meg Rivers, editor-in-chief of Pharmaceutical Executive, her experiences working in the industry, specifically in the vaccines space, as well as what it was like for her moving up the ranks as a woman. Other topics discussed include Trelstad’s predictions for more women working at the C-suite level, the inner workings of the Bill & Melinda Gates Medical Research Institute (including work on an infant probiotic), insight into her personal journey, and more.
Amanda Powers-Han, chief marketing officer at Greater Than One, has a couple of decades in the industry and is always on top of the latest trends in marketing and media for the pharma industry. She talks with senior editor Fran Pollaro about the ascension of social media as an incremental investment to one that is foundational. The pair delve into the honed focus on HCPs, especially in the rare disease space, building out sophisticated targeting strategies via multiple data partners, and the different uses across the social landscape, especially with video—from HCP social sites like Dermo and Medscape to the topical Twitter and its recognized peers like TikTok, Facebook, LinkedIn, and YouTube.
Cell and gene therapies are at the tip of everyone’s tongues in biopharma. Significant headway has been made in this space, though there is more research that needs to be done and many more therapeutic areas to eventually apply this method of treatment to. Chris Fox, president of Novartis Gene Therapies, shares insights into her work with gene therapies and discusses commercialization challenges. Through its gene therapies business, Novartis builds on the capabilities created through its experience with Zolgensma, a gene therapy for spinal muscular atrophy. Fox also dives into how she entered the pharma space, her role at Novartis, balancing work and home life, and what the Novartis team is most proud of from 2022 as well as what they are most excited about in 2023.
As a society and industry, we’re emerging out of a period of hyper-accelerated digital and virtual growth, a positive born out of the COVID-19 pandemic. Many in the industry are wondering how the sales force is going to look and how they’re going to approach and communicate effectively with HCPs and patients. Pratap Khedkar, CEO of ZS, discusses this time of change with senior editor, Fran Pollaro, as well as the implications associated with the Inflation Reduction Act, the focus and importance of patient-centricity, what we might see in 2023 in the sales and marketing vertical, and more.
On this week’s episode, Meg Rivers, editor-in-chief, and Miranda Schmalfuhs, group social media editor, speak with Steve Paul, chairman of the board, president, and CEO of Karuna Therapeutics, as well as Andrew Miller, founder and chief operating officer of Karuna Therapeutics. Miller was also one of Pharm Exec’s 2020 Emerging Pharma Leaders.The editors speak with Paul and Miller about the following: 1) their journey into pharma; 2) the factors that impact their decision to pursue any individual drug product; 3) the mental health/disorder treatment landscape; 4) what treatment has been like, historically, for schizophrenia and psychosis in Alzheimer's disease; 5) the company’s drug, KarXT, which is being evaluated in schizophrenia and psychosis in Alzheimer's disease; and 6) potential marketing and commercialization challenges for KarXT.
Marcella Milliet Sciorra, Chief Marketing Officer at DeepIntent, discusses Connected TV, or CTV, how it differs from over the top, and how CTV fits into the future of pharmaceutical marketing.
In episode 121 of the Pharm Exec Podcast, Nathalie Dompé, co-CEO of Dompé Pharmaceuticals, shares a glimpse into her journey in the pharma industry, her leadership style, the differences in working in leadership in the United States vs. Europe (Italy, specifically), and technologies in the biopharma industry. Meg Rivers, editor-in-chief, and Miranda Schmalfuhs, group social media editor, also talk to Dompé about: 1) launching a rare disease drug in the United States, the commercial/sales/marketing challenges, and what the company learned in the process; 2) how launching a rare disease drug differs from other drugs as it relates to the commercialization phase; 3) how can the industry can best meet the needs of patients and health systems; 4) balancing family/home life and work.
In episode 120, Nico Saraceno, editor of Pharmaceutical Commerce and host of the Pharmaceutical Commerce Podcast, and Andy Studna, associate editor and cohost of the Applied Clinical Trials Podcast, discuss what their respective podcasts offer to listeners, best guests, and more.
Listen to the Applied Clinical Trials Podcast: https://www.appliedclinicaltrialsonline.com/editorial-podcasts Listen to the Pharmaceutical Commerce Podcast: https://www.pharmaceuticalcommerce.com/editorial-podcasts
Sarah McKinnon, Senior Art Director at The Grey Group, discusses her entrance into the advertising world through blending art and science in school, understanding the connection between human health and storytelling, her own experiences as a patient along with a healthy dose of grit and passion to inform her audiences and her career.
In episode 119, Doina Ionescu, Managing Director, UK & ROI, at Merck, discusses her career journey, gender discrimination in the workplace, her role in the ABPI, and lessons she's taken from Queen Elizabeth II.
In episode 118, Paula Brown Stafford, CEO of Novan, discusses the company’s upcoming NDA filing for its topical agent for molluscum contagiosum, what commercialization could look like and her goals for the future.
In episode 117, Helen Sabzevari, CEO of Precigen, discusses her drive to study science as a Persian-born woman, the opportunities she’s had to research immunology, and how she’s now developing next-generation CAR-T treatments for cancer, in addition to other therapies.
In episode 116, Dr. Greg Rippon, vice president and chief medical partner at Genentech, discusses his work in Alzheimer’s and his outlook for the future of the therapeutic space.
In episode 115, Raj Verma, chief diversity, culture, and experience officer at Sanofi, discusses the various ways people see diversity around the world and how companies should be building diversity, equity, and inclusion into a company’s everyday fabric.
Proximyl Health’s Halen Dang, VP, Creative Director of Art and Carrie Morris, VP, Creative Director of Copy discuss remote teamwork and how to successfully lead agency creative teams with hybrid schedules.
In episode 114, Tiago Reis Marques, MD, PhD, CEO of Pasithea Therapeutics, discusses why it’s important to manage high levels of workplace stress, and how companies can help employees in need.
Listen to the latest episode of The Pharmaceutical Commerce Podcast: https://www.pharmaceuticalcommerce.com/view/making-the-commercialization-process-worthwhile
In episode 113, Indranil Bagchi, senior vice president and worldwide head, value and access at Novartis, and member of Pharmaceutical Executive Editorial Advisory Board, discusses the challenges of reaching patients and what he believes can help improve the situation.
Listen to the latest Pharmaceutical Commerce podcast: bit.ly/3uyWD8d
Carolyn O’Neill, Chief Creative Officer of Centron discusses their APEX-award winning global disease awareness campaign for both HCPs and patients, “Dimensionalizing the Patient Experience in PNH.” PNH or paroxysmal nocturnal hemoglobinuria is a rare immune disorder that attacks a person’s red blood cells. The campaign was meant to build on it is not an inherited disease and people’s symptoms don’t exhibit externally, usually appearing in mid-life and portray the feelings of a PNH sufferer.
Nima Farzan, CEO of Kinnate, who was one of Pharmaceutical Executive’s Emerging Pharma Leaders in 2013, discusses how he’s successfully navigated his career path, from building a foundation in pharma to growing his expertise in biotech.
Listen to the latest Pharmaceutical Commerce podcast: https://bit.ly/3uyWD8d
Nexus Pharmaceuticals' Chief Strategy Officer Omair Ahmed discusses their APEX-award winning EMERPHED™ campaign, which built on the ideas of simplification, safety and stability to enhance their hospital-delivered product and support their field sales reps.
Kevin Ali, CEO of Organon, talks about how’s he’s lead the launch of a new niche company for women’s health, and what he hopes it can achieve.
Ken Winell, chief technology officer of Greater Than One, talks about the metaverse and the potential it has to serve the pharma industry.
CDM Princeton’s Senior Creative Vice President John England discuss the company’s APEX-award winning Ilumya campaign “Defy the Laws of Psoriasis,” which used multiple innovative ideas including an AR focused in-person interactive piece, a upward scrolling website and more.
Myrto Kontaxi, a partner in the Biopharma Sustainability Roundtable, and lead author on its updated Biopharma Investor ESG Communications Guidance; and Victoria Emerick, global head of sustainability strategy and operations at Bristol Myers Squibb, a Biopharma Sustainability Roundtable participant, and a key contributor to the Guidance development process, discuss the growing demand for better communication about ESG strategy and performance, and how the updated ESG Guidance can help both biopharma companies and investors respond.
Glue Advertising's Cindy Machles, CEO and Co-founder & Nate Whipple, Producer, discuss their APEX-award winning respiratory campaign "For My Lung Health" delivered through videos, SEM, and a website--in English and Spanish--as an educational initiative by ATS and CHEST to inform people of color about lung health.
In episode 108, the rest of the PharmExec editorial staff join Elaine and Miranda to give more insight into the profiles they've written about the eleven members of our 2022 Emerging Pharma Leaders. Read their profiles in our May issue here: https://www.pharmexec.com/view/epl-2022
Congratulations to our 2022 EPLs: Naveen Bazaj, Gardner Gendron, Aida Habtezion, Matthew J. Hawryluk, Charmaine Lykins, Divya Chadha Manek, Susan Pandya, Matthew R. Price, Quiona Russell, Patricia Torr, and Shetal Vyas!
Biolumina's Troy Clark, SVP, Creative Director, and Anne Brown, SVP, Creative Director, Copy discuss their APEX-award winning website "Be in the Know" for AstraZeneca's metastatic non-small cell lung cancer (NSCLC) disease state education efforts.
In episode 107, Camille Hertzka, VP, head of oncology US medical at AstraZeneca, talks about her experience as a leader in oncology over the years and to expect from the space moving into the future.
In episode 106, Christi Shaw, CEO of Kite, a Gilead Company, talks about how CAR T-cell therapies are impacting cancer care and the lessons she’s learned along her career path.
In episode 105, Rolf Hoenger, area head of Latin America at Roche Pharma, talks about the current pharma landscape in Latin America and his experiences as a leader in this area.
In episode 104, Susanne Schaffert, president of Novartis Oncology, discusses her career journey, which has combined both a passion for the arts and science, and how she believes the two can work together in pharma.
Robert Clarke, CEO and co-founder of Kinaset Therapeutics, talks about developing inhaled therapies to fight asthma and COPD, which is especially relevant as COVID-19 poses significant problems for sufferers.
In episode 102, Mike Devoy, chief medical officer of Bayer, also executive vice president of medical affairs and pharmacovigilance for Bayer’s Pharmaceuticals Division, discusses how innovation, including the digitalization of healthcare delivery, and breakthrough technologies can help people make the most out of the longer lives they’re living today.
Bruno Larvol, CEO and founder of Larvol, discusses how he is invested in the digital world, both personally and professionally, and the impact it can have.
Our milestone 100th episode includes Lisa Henderson, group editorial director; Julian Upton, European and online editor; Fran Pollaro, senior editor; and Andy Studna, associate editor, discussing industry trends in areas such as Chinese biotech, corporate branding, psychedelic medicines, and market access barriers that they've written up for our January issue.
Read them here: https://www.pharmexec.com/view/our-view-on-2022-pharm-exec-s-annual-industry-outlook
Bill Sibold, executive vice president and head of Sanofi Genzyme, talks about his work in specialty care over the past 10 years and what makes it unique.
Giacomo Chiesi, Head of Global Rare Diseases at the Chiesi Group, discusses what it has been like growing up around pharma, and how he’s turned a family passion into his own dedicated career path.
Mike Ward, Global Head of Thought Leadership in the Decision Resources Group at Clarivate, discusses PharmExec’s 2022 pipeline report, which appears in our December issue. Mike goes behind the numbers and provides some interesting insights from the report provided by Clarivate.
Tim Whitten, CEO and president of Taiho Oncology, discusses how innovative thinking—from developing new therapies to creating a podcast for employees during COVID—has played an important role in his professional journey.
Jeff Stoll, US Life Sciences Strategy Leader at KPM, talks about some of the highlights from KPMG’s recent Global Pharma CEO Outlook report.
Amie Krause, Senior Vice President and Chief People Officer, and Kristin Yarema, Chief Commercial Officer, of Atara Biotherapeutics, talk about gender diversity in the c-suite and how that can benefit a company both internally and externally.
Michael Petroutsas, Senior Vice President and Head of GSK’s US Oncology Business Unit, talks about how his background has taught him the importance of connecting with patients on their level and how he brings that mentality to GSK.
Tom McCourt, CEO of Ironwood Pharmaceuticals, talks about his 30-plus years in the gastrointestinal space, including his experiences bringing top GI medicines Prilosec, Nexium, Entocort, Zelnorm, and Linzess to market.
Dr. Michael Henderson, chief business officer of BridgeBio Pharma, and one of Pharm Exec’s 2021 Emerging Pharma Leaders, discusses how his company goes beyond the traditional “hand off” approach between academia and industry, and looks to partner with institutions early on to fill important voids in drug development.
Dr. Edith Perez, Chief Medical Officer of Bolt Biotherapeutics, discusses how she approaches drug development in oncology, and what she contributes outside of work to help raise awareness for cancer.
Audrey Greenberg, co-founder and executive managing director of the Center for Breakthrough Medicines and Discovery Labs, discusses how cell and gene therapy has turned Philadelphia into Cellicon Valley, and how her organization is playing a role in that growth even beyond the city’s boarders.
Yan Chen, CEO of Elpis Biopharmaceuticals, discusses how she transformed her scientific background into launching her own biotech.
Arthur Kuan, CEO of CG Oncology, talks about the present and future of bladder cancer therapies, and how he’s committed to making a difference.
Cherie Davies, SVP, Executive Creative Director at FCB Chicago, talks about inspiring award-winning creative, especially in COVID times.
Emma Chaffin, vice president and country head of Galapagos UK, talks about how she has dealt with her own cancer diagnosis and the effects it has had on her life and work in pharma.
Teresa Bitetti, President of the Global Oncology Business Unit at Takeda Pharmaceuticals discusses the dynamic nature of the oncology space, and how leadership style and corporate culture play an important role in managing such a business.
Judy Stewart, head of US vaccines at GSK, talks about the effects of people missing their recommended vaccinations during the pandemic and the importance of delivering a message of value for vaccines.
Tina and Kathy Delaney, CCO of Publicis Health/Saatchi Wellness, chat about creative inspiration, trends and surreal career moments in this episode of Behind the Creative.
Mike Starich, CEO of Orion Talent, and Dr. Armand Balboni, CEO of Appili Therapeutics, discuss how veterans have specific skills and qualities that can set them up for success in pharma, and what the industry can do to uncover their potential.
Darrell Wakefield, Franchise Head, Solid Tumor, Sanofi Genzyme, talks creative impact on brand success.
Since 2008, Pharmaceutical Executive has recognized a class of biopharma professionals to receive the title Emerging Pharma Leader. This year, along with their profiles in our May issue, our editorial team presents a webcast featuring the winners and their up-and-coming perspectives on a range of industry topics.
Get a full list of our #2021EPL and read their profiles here:https://www.pharmexec.com/view/epl-2021
Sandor Schoichet, an independent advisor, and director of Meridian Management Consultants based in San Francisco, and Pharm Exec’s Sustainability columnist, and his co-collaborator, Thomas Scheiwiller, an independent advisor and board member based in Zurich, discuss many of the topics we touch on today in regard to biopharma’s approach to integrating environmental, social, and governance, or ESG, issues into business strategy.
Shaheed Peera, President, Founder and CEO of The Creative Floor Awards, London, and Global Creative Lead for Reckitt Benckiser ECom, talks about inspiring award-winning creative, reflects on his time as President on Cannes, and provides some insight on his award show The Creative Floor as well as a few tips about the inaugural PharmExec APEX Awards
Submit your PE APEX nominations here: https://apex.pharmexec.com/pages/apex-home?utm_source=linkedin&utm_medium=social&utm_campaign=PE
Dr. Michele Cleary, CEO of the Mark Foundation for Cancer Research, discusses how the foundation has navigated COVID to help keep critical cancer research going throughout the pandemic.
John Furey, CEO of Imvax and an Editorial Advisory Board member for Pharm Exec, discusses some leadership principles he learned while playing rugby as a young man in Ireland, and how those tenets can translate to the C-suite.
Uche Iloeje, Vice President medical affairs Mirdametenib at SpringWorks Therapeutics, shares his experience after he became stranded in Nigeria for five months and the valuable leadership lessons he learned.
Paul Shawah, Executive Vice President of Strategy at Veeva Systems, looks back at the past year of the pandemic to see the digital transformation of pharma’s interaction with healthcare professionals.
Kevin Buckley, founder of Torrey Pines Law Group, and Neil Thompson, a patent agent with the firm, discuss IP strategy as it relates to pharma and artificial intelligence.
Joel Marcus, founder and executive chairman of Alexandria Real Estate Equities, and founder and CEO of Alexandria Venture Investments, discusses the drive to bring pharma manufacturing back to a company’s home country and the issues involved in doing so.
Scott Nawrocki, managing director of digital investigations and cyber defense at Nardello & Co., discusses cybersecurity in pharma, including topics from prevention to crisis management.
Editorial Director, Lisa Henderson; European and online editor, Julian Upton; Senior Editor, Elaine Quilici ;and Assistant Editors of Pharmaceutical Executive, Miranda Schmalfuhs and Andy Studna, discuss some exciting industry trends for 2021, which they recently wrote for the January issue.
Gregg Beloff, co-founder of Danforth Advisors, discusses the banner year biotech IPOs had in 2020, the drive behind that boom, and what the future of industry IPOs might look like
Rich Horgan, founder and president of Cure Rare Disease(CRD), discusses how he sprang into action when his brother was diagnosed with Duchenne muscular dystrophy, by starting a nonprofit biotech to help find a cure.
Sacha Ward, chief client officer of Point of Care Network, discusses how COVID has affected the roles of nurse practitioners and physician assistants, and why marketing managers should take a moment to understand this growing group of health care influencers.
Krystle Buntemeyer, president of SCORR Marketing, and Bharat Mehta, co-founder of PharmaCompass, discuss a new, free online tool called Pipeline Prospector, which they recently launched in collaboration. The tool aims to provide pharma executives with industry data, including deal and pipeline information, to help them make more informed decisions.
Dr. Gregg Sylvester, chief medical officer of Seqirus, discusses the importance of vaccinating against the seasonal flu amid the COVID pandemic, and how the two viruses should be considered in light of each other.
Panna Sharma, CEO of Lantern Pharma, discusses garage biotech, what he’s learned from the culture, and how it might help transform certain areas of pharma, including innovation and pricing.
Sanjeev Luther, president and CEO of Rafael Pharmaceuticals, discusses how he managed to turn around a company on the brink of bankruptcy and advance clinical trials for its lead cancer drug through COVID-19.
Dr. Neil Hayward, CEO and founder of eXlthera, is here to discuss his company, which is developing Factor XI inhibitor antithrombotics that are attacking blood clots from a new angle and are giving patients new hope.
George Baxter, CEO of Edinburgh Innovations, is here to discuss the company's commercialization model, and how his group is bringing innovation to market in Scotland.
Jack Khattar, president and CEO of Supernus Pharmaceuticals, talks about his experience bringing ADHD drugs to market in a challenging environment.
Eric Turbiville, author of the recently published book “The Perfect Leadership Triad: How Top Executives Maximize Productivity through People, Coaching, and Performance," a 25-year pharma veteran, credentialed executive coach, and director of mentoring for the Southwest region of the Healthcare Businesswomen’s Association says there are three leadership principles can help executives through tumultuous times, and is here to discuss how they can impact success.
Kurt Orlofski, CEO of Pharmaceutical Associates Inc., discusses what the pharmaceutical supply chain might look like post COVID-19, and how companies can prepare for that.
Jim and Cindy DiBiasi, co-founders of 3D Communications, talk about how to prepare for virtual high-level meetings, such as important regulatory presentations and keynote addresses, in the wake of COVID-19.
Tim Walbert, CEO of Horizon Therapeutics, shares his unique perspective on managing the Chicago location of the company through COVID-19, in light of the fact that he himself is immunocompromised.
Janice Kranz, co-founder of Eikonizo Therapeutics, bring us up to date on how targeting tau to fight Alzheimer’s and other neurodegenerative diseases is making waves in the CNS space.
Dr. Jonathan Gertler, CEO of Back Bay Life Science Advisors, and Dr. Stephan Gauldie, Managing Director of Back Bay, talk about the new guidelines set forth by FDA in regard to gene therapy, and what those new parameters mean for pharma and biotech.
Pratap Khedkar, managing principal of ZS Associates, talks about pharma’s scenario planning amid COVID-19 as it looks to settle into a new normal.
Lew Bender, founder of Intensity Therapeutics and the inventor of Intensity’s DfuseRx platform technology, discusses the technology that allows the company’s therapeutic products to be injected directly into solid tumors, this innovative process successfully kills tumors and activates an immune response to shut down cancer cells throughout the body.
Kathrin Jansen, Senior Vice President and Head of Vaccine Research and Development at Pfizer, talks about the challenges of creating a new maternal vaccine for respiratory syncytial virus, also known as RSV, currently being administered to pregnant women in trials, in the hopes of protecting their infants.
Chris Paquette, DeepIntent co-founder and CEO, talks about the evolution of digital marketing in pharma, specifically, how to approach data and technology usage in a privacy-first world.
Barbara Ryan, founder of Barbara Ryan Advisors, a member of PharmExec’s editorial advisory board, and the founder of Fabulous Pharma Females discusses the strong community she’s built providing women the opportunity to connect with each other and reinforce their shared commitment to one another.
Yuval Cohen, CEO of Corbus Pharmaceuticals, talks about cannabinoids, the differences between natural and synthetic products, and how biotechs and pharma are using them to treat disease today.
Dr. Eric von Hofe, Chief Scientific Officer at NuGenerex Immuno-Oncology talks about the recent outbreak of Wuhan coronavirus around the world and how biotechs and pharma are jumping in to help find a solution.
Mike Strazzella, head of federal government relations for Buchanan Ingersoll & Rooney, talks about pricing issues in the pharmaceutical industry, the challenges he encounters, and what he believes needs to change in the industry going forward.
Pharm Exec speaks with Nigel Breakwell and Ben Randal, co-founders of Dot I/O Health. Nigel and Ben talk about how they’re using data science in the health and life sciences industries to help clients navigate emerging markets.
Pharm Exec editors discuss the themes chosen for the January issue focusing on industry trends for the coming year.
Heather Monte, Director of Operations for DirectRx, talks about the specialty pharma’s new Patient Scorecard, which aims to identify and improve adherence by reporting patients’ prescription patterns to doctors.
Julia Owens, co-founder and CEO of Millendo Therapeutics talks about how to keep a company on the path to success, even when there are bumps in the road. She discusses the value of focusing on strengths and how that is currently working for Millendo in the endocrine space.
William Lewis, chairman and CEO of Insmed talks about the approval of the company’s drug Arikayce through the FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs, some ideas that he spoke about on the recent NORD panel about innovative and ethical partnerships, and Insmed’s pipeline and progress.
Pharm Exec editors discuss the articles they focused on for the November Annual Pipeline Report.
Sven Klingemann, research director at Reputation Institute talks about pharma’s negative public perception and what the industry can do to improve it.
Pharm Exec editors interview Mark Glickman, Chief Commercial Officer of Esperion Therapeutics. Glickman discusses the overall cholesterol-lowering space and how it’s planning to add a new therapeutic option for patients, what it means to establish a new therapy in a statin-dominated market, market research approaches, and more.
Jeannine Lynch, senior director at BioMarin Pharmaceuticals, oversees patient access services and talks with editors about the patient journey in regard to receiving therapies, how to engage with patients more effectively, and where she sees the pharma industry in terms of patient engagement and patient centricity.
Janssen’s company group chairman of Europe, Middle East, and Africa operations, Kris Sterkens speaks with Pharm Exec editors. Kris talks about his finance background, global pricing issues, and challenges and opportunities for EMEA biopharma breaking into the US market.
Apellis’ CEO and co-founder, Dr. Cedric Francois talks with editors about his unusual pharma journey, which has included research, clinical work, and the launch of two startups. Today, he’s here to share what he’s learned along the way and how he’s using that experience to improve lives.
Christine Sakdalan, Head of Franchise Strategy and Customer Solutions at Janssen Pharmaceutical talks with Pharm Exec editors about how patient-centricity fuels innovation, the difference between patient and customer centricity, and educational programs that need to be implemented for patients, providers, and payers.
Pharm Exec editors sit down with Mark Velleca, CEO of G1 Therapeutics. In this episode, Mark talks about how he differentiates himself in the oncology field, why he considers G1 Therapeutics an "old school company," and about the North Carolina biotech landscape.
Pharm Exec editors share insights into what they've been working on this summer for the June, July, and August issues; plus a sneak peek into what's coming in September!
Robert Finkel, the CEO of The FreshBlood Group talks with Pharm Exec editors about the positives and negatives of pharma’s marketing needs, the details and evolution around founding The FreshBlood Group, and how emerging pharma and biotech companies can budget in successful marketing.
Cameron Turtle, Chief Business Officer of Eidos Therapeutics, Robin Toft, Founder and CEO of The Toft Group Executive Search and Sabrina Johnson, President and CEO, Daré Bioscience join Pharm Exec editors to talk about the future of the life sciences executive.
Pharm Exec editors speak with Jigar Raythatha, CEO of Constellation Pharmaceuticals. He talks about his roles, the importance of having a Plan B in biotech, creating a translationally enabled company, and how he leads his team at Constellation.
Pharm Exec's European Editor, Julian Upton, speaks with Johnson & Johnson's Jennifer Turgiss, VP Behavior Science & Advanced Analytics group. In their interview, Turgiss discusses behavioral strategies to the health and wellness solutions being developed at J&J.
Editor-in-Chief Lisa Henderson speaks with Bill Newell, CEO of Sutro Biopharma about his background in corporate law and how it helps him in his role as a biotech executive, the importance of collaboration between big pharma and biotech, a story about keeping the San Francisco Giants in the Bay area, and other analogies around sports related to running a biotech.
Pharm Exec editors interview Anna Sundgren, the renal disease strategy leader, Global Medicines Development at AstraZeneca, about the current CVRM landscape, challenges to renal drug development, and new therapeutics for chronic kidney disease. This podcast was brought to you by QxMD.
Pharm Exec's European Editor, Julian Upton, caught up with Ben Wiegand, head of J&J's World Without Disease Accelerator unit, at eyeforpharma Barcelona. They talk about Wiegand's panel "Uniting Patients, Providers, and Payers to Bring Preventative Care to Life," and J&J's disease prevention and interception activities. This podcast was brought to you by QxMD.
Michelle Maskaly and Christen Harm speak with Bill Carson, President & CEO of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Kabir Nath, President & CEO of Otsuka North America Pharmaceuticals about digital medicine, mental health therapies, and creating a smooth and collaborative relationship between R&D and commercial.
Pharm Exec editors talk with Seth Lederman, co-founder, CEO and chairman of Tonix Pharmaceuticals about how to navigate creating drugs for conditions such as PTSD and AIDS, running a business, and academia.
Pharm Exec editors sit down with Bob Ward, chairman and CEO of Eloxx Pharmaceuticals, to talk about his personal, as well as Eloxx’s, commitment to working with patient advocacy groups, how to attract talent, and how to put together a great team.
Michelle Maskaly and Christen Harm talk with David Shao, CEO of Yisheng Biopharma, about what’s driving China’s exploding pharma and biotech industries, as well as the country’s push to become a global life science leader.
Michelle Maskaly and Christen Harm sit down with Editor-in-Chief Lisa Henderson and European Editor Julian Upton to discuss the industry trends featured in Pharm Exec's January 2019 issue.
Pharm Exec editors Michelle Maskaly and Christen Harm speak with Raymond Sanchez, senior vice president of Global Clinical Development at Otsuka Pharmaceutical Development & Commercialization. Raymond talks about his switch from academia to clinical development, the sobering affect of seeing a drug he helped develop on the pharmacy shelf, and how he uses mindfulness to encourage and lead his team.
Nicola Kayel, Vice President of Marketing at Salix Pharmaceuticals, speaks with Pharm Exec editors about the challenges and strategies for marketing drugs that treat embarrassing conditions, like irritable bowel syndrome. She also discusses the company's recent plunge into virtual and augmented reality and how it plays a role in the future for healthcare professionals.
Jack Bailey, president of US pharmaceuticals for GlaxoSmithKline, talks with Christen Harm and Michelle Maskaly, about the biopharma landscape in the southeastern part of the United States, as part of Pharm Exec’s ongoing series that looks at growing biotech innovation hubs across the country. Bailey gives unmatched insights about the efforts North Carolina has put into growing, attracting, and retaining life science startups, specifically in the Raleigh-Durham area, as well as addresses challenges such as access to venture capital.
Pharm Exec Editorial Director Lisa Henderson and European Editor Julian Upton talk with Michelle Maskaly and Christen Harm about the magazine’s recent pharmaceutical pipeline report which was published in the November 2018 issue. Topics include cannabis, CAR-T therapy, opioids, biosimilars, and Alzheimer’s.
Christen and Michelle talk with Mei Mei Hu, CEO of United Neuroscience, about how being open to pivoting from your original plan can create a number of opportunities for an executive and their company, as well as how her executive team successfully manages a remote workforce spread across three continents. In a hilarious conversation about balancing professional and personal life, Hu also talks about how she ended up leading a spinout of her family’s life sciences business after a career in consulting, despite vowing to never be a part of the biotech world.
Michelle and Christen sit down with one of this year's Emerging Pharma Leaders, Christopher Boone, the head of real-world data and analytics center of excellence at Pfizer. We discuss what peaked Boone's interest in public health and data; the progression of how pharma and data have merged; what challenges pharma faces with data and what lies ahead; and where he got his infamous twitter handle.
On Target Laboratories, CEO and Co-Founder, Martin R. Low and Philip S. Low, whose work the company is based off of and is also a co-founder of the company, join Christen Harm and Michelle Maskaly to talk about the ups and downs of commercializing research that has been previously shelved. They share how they approached another company to license the technology, why being persistent is a good thing if you truly believe the research can make a difference in the lives of patients, and talk about what it’s been like to work with each other in a business, given that they are brothers. Martin R. Low also discusses what it’s been like for him to run a pharma company, since his prior expertise ranges a variety of other industries outside of pharma.
Pharm Exec’s Editor-in-Chief Lisa Henderson and European Editor Julian Upton join Christen Harm and Michelle Maskaly to talk about the topic of specialty pharma, which was featured in the magazine’s September issue. They discuss the marketing, logistics, pricing, and other challenges executives in the specialty pharma industry face, as well as dive into the forces that are driving this segment of the industry and what the future will look like.
Learn how pharma companies are using robotics and artificial intelligence when it comes to patient care, what the funding landscape is for businesses in this sector, and as a member of the c-suite find out what you need to do now to be at the forefront of this emerging technology.
Nancy Thornberry, CEO of Kallyope, talks with Michelle Maskaly and Christen Harm about New York City as an emerging hotspot for biotech incubators, and the challenges and opportunities related to space, location, recruitment, and funding.
Jeffrey Nau is CEO of Oyster Point Pharma, a clinical stage pharmaceutical company focused on developing commercial therapies dealing with parasympathetic pathways. In a climate where oncology and rare diseases get most of the attention, Nau talks about what it’s like working on diseases that don’t get the same press, like dry eye, which is the focus of their current Phase 2 clinical trial. How this impacts raising capital and other bumps in the road he has come across. Having extensive experience with raising startup money, Nau outlines some best practices when it comes to funding.
Gil Van Bokkelen, CEO and co-founder of Athersys, talks about a pivotal moment during medical school that led him and his co-founders to eventually launch Athersys, the decision to start the company in Ohio instead of his native Northern California, and the secret to staying resilient in the c-suite even when facing extraordinary challenges.
Former NFL star and current sports broadcaster, Solomon Wilcots talks about the intersection of sports and biopharma. He discusses traumatic brain injuries and whether or not the NFL is doing enough about it, projects he has been working on that match professional athletes who are passionate about a certain disease with biopharma companies, and how lessons from the football field can be applied to the boardroom.
Michelle Maskaly and Christen Harm host one of Pharm Exec's Emerging Pharma Leaders, Sabina Ewing, vice president of business technology for Pfizer, and discuss the difference and importance of mentoring and sponsoring in business and pharma.
Leadership Tip from Sabina Ewing.
Michelle Maskaly and Christen Harm host the entire Pharmaceutical Executive editorial team on this episode, as we each talk about our Brands of the Year selections and why we chose them.
Leadership Tip from Molly Herbert.
Tim Sullivan, CFO of Apellis Pharmaceuticals, gives an inside look at what it takes to be the CFO of a development-stage biotech company, and what business skills someone needs to succeed in that type of position.
Leadership tip from Tim Sullivan.
Pharm Exec editors discuss key takeaways from a variety of industry conferences that took place across the globe.
Leadership Tip by Julia Cheek, CEO of EverlyWell.
Christen Harm and Michelle Maskaly interview Lara Sullivan, founder and president of SpringWorks Therapeutics, about the differences in working for legacy pharma vs. small biotech start-ups.
Leadership Tip from Lara Sullivan.
Dr. William Soliman shares the story of how the Accreditation Council for Medical Affairs went from an idea in his head to a training program today that has enrolled more than 3,000 people and is setting new standards for medical affairs professionals.
Leadership Tip from William Soliman.
In this episode, Michelle Maskaly and Christen Harm talk with Editor-in-Chief Lisa Henderson and European Editor Julian Upton about outcomes-based contracting from the March issue.
Leadership tip from Molly Herbert.
Michelle Maskaly and Christen Harm talk to Devyn Smith, chief strategy officer and head of operations for Sigilon Therapeutics on the topic of pharma's reputation, both in the US and Europe.
Leadership Tip from Devyn Smith.
In this episode, Michelle Maskaly and Christen Harm speak with Marc O'Connor, chief operating officer at Curant Health, and Pharm Exec's Editor-in-Chief, Lisa Henderson with insights on the JPMorgan Healthcare Conference that took place at the beginning of January.
Leadership Tip from Marc O'Connor, chief operating officer at Curant Health.
In this podcast, Pharmaceutical Executive editors discuss the 2018 pharma trends, specifically biosimilars and eEnablement, and takeaways from the 2017 Veeva European Commercial Summit.
Leadership Tip from Julia Cheek, CEO of EverlyWell.